CYBN:CC News and Press, CYBIN INC. From 10/06/22

Cybin (NYSE American: CYBN) (NEO: CYBN) , a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(R), today provided an update on its intellectual property (“IP”) progress in support of its research and development strategy. According to the update, Cyb...

-- Cybin strengthens its intellectual property library with more than 20 active patent filings across six patent families, and multiple license agreements that provide access to over 35 patents and applications -- Cybin Inc. ( NEO:CYBN ) (NYSE AMERICAN:CYBN) (“...

Cybin (NEO: CYBN) (NYSE American: CYBN ), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), and its wholly owned subsidiary, Cybin IRL Limited, have signed a deal with Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) to acquire an exclusive...

– Provides access to large catalog of compounds complementary to Company’s preclinical assets – – Strengthens drug discovery and development platform to build future potential novel drug candidates – – Suppo...

TORONTO, Sept. 27, 2022 (GLOBE NEWSWIRE) -- Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) (“Mindset”) , a drug discovery company developing novel, optimized, next-generation psychedelic and non-psychedelic medications to treat neuropsychiatric and neuro...

Cybin (NYSE American: CYBN) (NEO: CYBN) is a biotechnology company focused on progressing Psychedelics to Therapeutics(TM). The company today announced its participation in upcoming conferences taking place in September and October 2022. The company’s CEO Doug Drysdale participated ...

Cybin Inc. ( NEO:CYBN ) (NYSE American:CYBN) (“ Cybin ” or the “ Company ”), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics TM , is pleased to announce its participation in the following upcoming conference...

Convergence, the biggest psychedelic culture and business conference in California, recently announced that Hamilton Morris would be a keynote speaker at the conference. Morris is a well-known advocate in the psychedelics space. In addition to being a scientific researcher, a journalist an...

-- Completion of Adelia milestones marks promising path toward clinical drug development -- Cybin Inc. ( NEO:CYBN ) (NYSE AMERICAN:CYBN) (“ Cybin ” or the “ Company ”), a biopharmaceutical company focused on progressing “Psy...

Microdosing is the practice of consuming low doses of hallucinogenic psychedelics such as LSD and psilocybin. This practice appears to be growing in popularity, with individuals who microdose touting the practice’s potential mental health benefits. These supposed benefits include im...